bullish

AIM Vaccine

AIM Vaccine (艾美疫苗) Pre-IPO Tearsheet (Refiled)

284 Views21 Sep 2021 10:16
AIM Vaccine is looking to raise US$1bn in its upcoming Hong Kong IPO. The deal is run by Goldman Sachs, CICC, China Securities, and Macquarie.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Clarence Chu
APAC IPOs & Placements
Aequitas Research
EquitiesEquity Capital Markets
  • AIM Vaccine (艾美疫苗) Pre-IPO Tearsheet (Refiled)
    21 Sep 2021
x